title: The Membrane Permeability Outcome study.
abstract: Many observational studies have consistently shown that high-flux hemodialysis has positive effects on the survival and morbidity of uremic patients when compared with low-flux hemodialysis. However, the HEMO study, a randomized trial designed to evaluate the effect of membrane permeability on patient survival, showed only an 8% non-statistically significant reduction of mortality, albeit a secondary analysis suggested an advantage for high-flux membranes in certain patient subgroups. The prospective, randomized Membrane Permeability Outcome (MPO) study investigated the impact of membrane permeability on survival in incident hemodialysis patients who had low albumin (≤4 g/dl) and normal albumin ( >4 g/dl) as separate randomization groups. Patients with serum albumin ≤4 g/dl had significantly better survival rates in the high-flux group compared with the low-flux group (p = 0.032). Moreover, a post-hoc secondary analysis showed that high-flux membranes may significantly improve survival in diabetic patients. No difference was found in patients with normal albumin levels. Considering the increasing number of dialysis patients with low serum albumin levels and with diabetes, the relevance of the MPO study led to the publication of a position statement by the European Renal Best Practice Advisory Board. This board strongly recommended that high-flux hemodialysis should be used for high-risk patients and, with a lower degree of evidence, even also for low-risk subjects due to the substantial reduction in β(2)-microglobulin levels observed in the high-flux group.
authors.forename: Francesco
authors.initials: F
authors.lastname: Locatelli
authors.forename: Andrea
authors.initials: A
authors.lastname: Cavalli
authors.forename: Celestina
authors.initials: C
authors.lastname: Manzoni
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pontoriero
mesh_terms: D006801:Humans; D008567:Membranes, Artificial; D010539:Permeability; D006435:Renal Dialysis / Q000295:instrumentation* / Q000379:methods; D051437:Renal Insufficiency / Q000097:blood / Q000401:mortality* / Q000628:therapy*; D012307:Risk Factors; D012709:Serum Albumin / Q000378:metabolism; D015996:Survival Rate
chemical_list: D008567:Membranes, Artificial; D012709:Serum Albumin